ArticleFrontiers in public health2016
Increase of Incidence and Mortality of Ovarian Cancer during 2003-2012 in Jiangsu Province, China.
Article in Frontiers in public health, 2016. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 16 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
16 citing papers in PubMed.
- Trends in the Incidence of Ovarian Cancer Among Premenopausal and Postmenopausal Women in the United States, 2001 to 2021.Cancers · 2025Article
- Observational
- Configurational analysis of ovarian cancer incidence in 30 provinces of China and its policy implications: a fuzzy-set qualitative comparative analysis approach.Frontiers in public health · 2024Article
- Temporal trends and projections of gynecological cancers in China, 2007-2030.BMC women's health · 2023Article
- Is there any difference in insulin resistance status between cases of benign and malignant ovarian neoplasms? A study on surrogate markers of insulin resistance in Indonesian non-diabetic women.Oncology letters · 2023Article
- The global, regional and national epidemiology, incidence, mortality, and burden of ovarian cancer.Health science reports · 2022Article
- Women's cancers in China: a spatio-temporal epidemiology analysis.BMC women's health · 2021Article
- Disease Burden and Attributable Risk Factors of Ovarian Cancer From 1990 to 2017: Findings From the Global Burden of Disease Study 2017.Frontiers in public health · 2021Article
- Aberrant Methylation Status of Tumour Suppressor Genes in Ovarian Cancer Tissue and Paired Plasma Samples.International journal of molecular sciences · 2019Article
- Clear differences in ovarian cancer incidence and trends by ethnicity among Asian Americans.Cancer epidemiology · 2019Article
- MiR-203a-3p regulates the biological behaviors of ovarian cancer cells through mediating the Akt/GSK-3β/Snail signaling pathway by targeting ATM.Journal of ovarian research · 2019Article
- Sphingosine kinase 2 inhibitor ABC294640 displays anti-epithelial ovarian cancer activities in vitro and in vivo.OncoTargets and therapy · 2019Article
- Recent Trends in Ovarian Cancer Incidence and Relative Survival in the United States by Race/Ethnicity and Histologic Subtypes.Cancer epidemiology, biomarkers & prevention : a publication of the American Association for Cancer Research, cosponsored by the American Society of Preventive Oncology · 2017Article
- Endoplasmic reticulum stress regulates proliferation, migration and invasion of human ovarian cancer SKOV3 cells through PI3K/AKT/mTOR signaling pathway.Cancer biomarkers : section A of Disease markers · 2017Article
- Epidemiology of ovarian cancer: a review.Cancer biology & medicine · 2017Article
- High-grade serous ovarian and fallopian tube carcinomas with similar clinicopathological characteristics might originate from serous tubal intraepithelial carcinoma in Chinese women.International journal of clinical and experimental pathology · 2017Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
purposeThe objective of this study is to investigate and analyze the epidemiologic characteristics and time trends of ovarian cancer incidence and mortality in Jiangsu Province of China during 2003-2012.
methodData were collected from eligible cancer registries in Jiangsu Province. Crude rates, age-specific rates, truncated age-standardized rate, and proportions of ovarian cancer were calculated. The Segi's World Population was used to calculate age-standardized rates for world (ASW). Poisson distribution was used to analyze the differences between urban and rural areas. Joinpoint regression was performed to estimate the annual percent change (APC) of ovarian cancer incidence/mortality.
resultsA total number of 4,401 new cases and 1,918 deaths were identified during period 2003-2012. The incidence and mortality ASW was 3.64/100,000 and 1.52/100,000, respectively. ASW of incidence was 4.48/100,000 in urban areas, while 3.04/100,000 in rural areas. The mortality of ASW was slight higher in urban areas than in rural areas. Age-specific incidence showed a peak at the age group of 60-64 years, whereas mortality peaked at age group of 65-69 years. A significant increase of incidence was observed from 2003 to 2006, with an APC of 34.0% (95% CI: 9.7, 63.7), the increasing rate declined since 2006 (APC = 3.3%, 95% CI: -3.5, 10.5). The mortality showed a gentle upward trend as compared with incidence, with an APC of 9.9% (95% CI: 7.7, 12.2) per year, continuously from 2003 to 2012. It is apparent that both incidence and mortality presented a rising trend in all areas, but urban were higher than that in rural areas.
conclusionOvarian cancer is a highly lethal disease which is becoming a significant public health problem in Chinese women. It is vital to improve the understanding of current status of ovarian cancer. Moreover, prevention and control policies should be formulated to reduce the disease burden of ovarian cancer in China.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.